{"brief_title": "A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer", "brief_summary": "The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer", "condition": ["Prostatic Neoplasms", "Metastases, Neoplasm"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["ZD4054 10 mg", "ZD4054 15 mg", "ZD4054 22.5 mg"], "description": ["1 x 10 mg oral tablets once daily", "1 x 10 mg + 2 x 2.5 mg oral tablets once daily", "2 x 10 mg + 2 x 2.5 mg oral tablets once daily"], "arm_group_label": ["ZD4054 10 mg", "ZD4054 15 mg", "ZD4054 22.5 mg"], "other_name": ["Zibotentan,", "Zibotentan", "Zibotentan"], "criteria": "Inclusion Criteria: - Men 18 years & older - Confirmed diagnosis of prostate cancer with bone metastases Exclusion Criteria: - No more than 2 prior chemotherapy regimens - No radiation, chemotherapy or bisphosphonates in the past 4 weeks", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "bone metastases", "mesh_term": ["Neoplasms", "Neoplasm Metastasis", "Prostatic Neoplasms"], "id": "NCT00055471"}